{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:41:52Z","timestamp":1787071312340,"version":"build-2736575974"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"Abstract<\/jats:title>\n \n Objective:<\/jats:title>\n To assess the role of omental and ovarian chemotherapy response score (CRS) and CA125 as a predictor of prognosis in patients with tubo-ovarian high-grade serous carcinoma (HGSC)\/primary peritoneal carcinoma (PPC) receiving neoadjuvant chemotherapy (NACT). In addition, to study the correlation of omental CRS with chemoresistance.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n A retrospective record review of patients with tubo-ovarian HGSC\/PPC receiving NACT followed by interval debulking surgery (IDS) between January 2012 and May 2020 was done. The slides of the omentum and ovarian tissue of the patients were retrieved and reviewed by a trained pathologist. During analysis, CRS 1 and CRS 2 were merged together for comparison against CRS 3.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n A total of 44 patients with a mean age of 54 years were included in the study. Among the patients, 29.5%, 38.6%, and 31.8% had a CRS of 1, 2, and 3, respectively, on the omental specimen and 31.8%, 43.2%, and 25% on the ovarian specimen. Median PFS and OS was significantly better with omental CRS 3 (\n P<\/jats:italic>\n = < 0.0001 and\n P<\/jats:italic>\n = < 0.00065). No significant difference in median OS of patients was noted with ovarian CRS 1, 2, or 3 (\n P<\/jats:italic>\n = 0.057); however, the median PFS was significantly better in patients with CRS 3 on ovarian tissue (\n P<\/jats:italic>\n = 0.036). Platinum resistance was significantly lower in patients with CRS 3 on omentum (\n P<\/jats:italic>\n = 0.001). The value of CA125 post NACT had a significant association with PFS on both univariate and multivariate analyses. There was no statistically significant correlation between CA125 and omental CRS.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n Omental CRS has a prognostic significance for patients with tubo-ovarian HGSC\/PPC receiving NACT and correlates significantly with PFS and OS. Ovarian CRS correlates significantly only with PFS. Post NACT CA125 value had a significant association with PFS.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/ijc.ijc_894_21","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:17Z","timestamp":1750982417000},"page":"17-22","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["The prognostic role of omental, ovarian chemotherapy response score and CA125 in predicting survival in patients with tubo-ovarian high-grade serous carcinoma\/primary peritoneal carcinoma receiving neoadjuvant chemotherapy"],"prefix":"10.4103","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1405-8735","authenticated-orcid":false,"given":"Ramya D.","family":"Ravi","sequence":"first","affiliation":[{"name":"Department of Gynecologic Oncology, St John\u2019s Medical College, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8459-1466","authenticated-orcid":false,"given":"Kiran A.","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, St John\u2019s Medical College, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1745-4706","authenticated-orcid":false,"given":"Geeta","family":"Acharya","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, St John\u2019s Medical College, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2430-4108","authenticated-orcid":false,"given":"Premalatha","family":"Siddharta","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, St John\u2019s Medical College, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4426-6914","authenticated-orcid":false,"given":"Gayatri","family":"Ravikumar","sequence":"additional","affiliation":[{"name":"Department of Pathology, St John\u2019s Medical College, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2302-7877","authenticated-orcid":false,"given":"Vishakha C.","family":"Bidkar","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, St John\u2019s Medical College, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2169-2566","authenticated-orcid":false,"given":"D","family":"Mohanapriya","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, St John\u2019s Medical College, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"R1-20250627","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics, 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"R2-20250627","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med"},{"key":"R3-20250627","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): An open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"key":"R4-20250627","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13048-016-0266-3","article-title":"The significance of the change pattern of serum CA125 level for judging prognosis and diagnosing recurrences of epithelial ovarian cancer","volume":"9","author":"Yang","year":"2016","journal-title":"J Ovarian Res"},{"key":"R5-20250627","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1200\/JCO.2014.60.5212","article-title":"Chemotherapy response score: Development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma","volume":"33","author":"B\u00f6hm","year":"2015","journal-title":"J Clin Oncol"},{"key":"R6-20250627","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ygyno.2018.08.042","article-title":"Prognostic implications of histological tumor regression (B\u00f6hm's score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma","volume":"151","author":"Rajkumar","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"15 Suppl","key":"R7-20250627","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1200\/JCO.2018.36.15_suppl.5516","article-title":"Survival analyses from a randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer with high tumor load (SCORPION trial)","volume":"36","author":"Fagotti","year":"2018","journal-title":"J Clin Oncol"},{"key":"R8-20250627","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann Oncol"},{"key":"R9-20250627","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/ijgc-2018-000092","article-title":"Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: Updated Chemotherapy Response Score (CRS) results","volume":"29","author":"Bohm","year":"2019","journal-title":"Int J Gynecol Cancer"},{"key":"R10-20250627","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/PGP.0000000000000513","article-title":"Assessment of a chemotherapy response score (CRS) system for tubo-ovarian high-grade serous carcinoma (HGSC)","volume":"38","author":"Ditzel","year":"2019","journal-title":"Int J Gynecol Pathol"},{"key":"R11-20250627","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/his.13399","article-title":"The chemotherapy response score is a useful histological predictor of prognosis in high-grade serous carcinoma","volume":"72","author":"Singh","year":"2018","journal-title":"Histopathology"},{"key":"R12-20250627","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/IGC.0000000000000945","article-title":"Prognostic role of histological tumor regression in patients receiving neoadjuvant chemotherapy for high-grade serous tubo-ovarian carcinoma","volume":"27","author":"Coghlan","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"R14-20250627","doi-asserted-by":"crossref","first-page":"778","DOI":"10.3389\/fonc.2019.00778","article-title":"Pathological chemotherapy response score in patients affected by high grade serous ovarian carcinoma: The prognostic role of omental and ovarian residual disease","volume":"9","author":"Santoro","year":"2019","journal-title":"Front Oncol"},{"key":"R15-20250627","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ygyno.2013.09.030","article-title":"Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery","volume":"131","author":"Muraji","year":"2013","journal-title":"Gynecol Oncol"}],"container-title":["Indian Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijc.ijc_894_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:44:28Z","timestamp":1787067868000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijc.ijc_894_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ijc.ijc_894_21","relation":{},"ISSN":["0019-509X","1998-4774"],"issn-type":[{"value":"0019-509X","type":"print"},{"value":"1998-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2021-07-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}